Investor Readiness Consulting

 Investor Readiness Consulting for Early Biotech & Start‑ups  

Schedule a Call

Align your development strategy with investor expectations to unlock funding

Our consultants bring decades of practical drug‑development expertise and direct involvement in investor due‑diligence processes. We guide early-stage companies using evidence‑based methodologies aligned with regulatory expectations and investor evaluation frameworks.

We support start‑ups and early biotech’s from discovery through Phase 1, providing Target Product Profiles (TPPs), Drug Development Plans (DDPs), Regulatory Roadmaps, and evidence‑driven strategic planning.  

Our mock due‑diligence assessments have strengthened multiple successful fundraising rounds by highlighting critical gaps early, and shaping robust development strategies.  

 

 

 

 

 

 

Our clients work directly with senior experts across regulatory affairs, clinical development, non‑clinical strategy, and CMC. This peer‑level engagement ensures your programme aligns with industry expectations and the scrutiny applied during investor evaluation and scientific due‑diligence.

We deliver transparent risk assessments, grounded forecasts, and clear, defensible strategic recommendations. Our long‑standing client relationships and repeat engagements reflect both the quality of our work and the confidence investors place in well‑prepared programmes.

Because we also work directly with investors to evaluate assets, we understand their expectations first‑hand, and this insight shapes the strategic recommendations we provide.

 

Who?

Start-Ups & Early Biotechs

This solution is ideal for start-ups and early biotechs who require support in their journey to attract investors, and gaining funding to further their research. 

What?

hVIVO's Role

By engaging with hVIVO's integrated team we help uncover gaps in data, develop investment critical documentation, complete mock due diligence and ensure you are investor ready.

When?

Major Inflection Points

hVIVO has significant experience working from the earliest phases of development, from discovery through to pre-clinical and phase I. 

Investor Readiness Consulting for Early Biotech & Start‑ups

Enquire now

Why Consider hVIVO

Guidance

 Grounded in extensive drug‑development and investor due‑diligence experience. 

Peer-to-Peer

Access to cross-functional drug‑development experts.

Agile

High-quality delivery reflected in strong customer loyalty and repeat engagements.

Our Investor Readiness Solution Includes

  • Strategic guidance informed by decades of real‑world drug‑development and due‑diligence experience.
  • Development or refinement of core investment‑critical documents: TPP, DDP, and Regulatory Roadmap.
  • Flexible expert resourcing to strengthen your internal team when needed.
  • Mock due‑diligence reviews and comprehensive gap analysis across scientific, clinical, operational, and regulatory domains.
  • Analytical and clinical development forecasting with scenario‑based budgeting.
  • Clinical development strategy design, financial modelling, and budget planning.

FAQs

It prepares early-stage biotech’s and start-ups for successful fundraising with strategic documents, risk assessment, forecasting, and expert guidance.

Start-ups and early-stage biotech’s operating between discovery and Phase 1 development.

 

A Target Product Profile, Drug Development Plan, and Regulatory Roadmap.

A proactive strategic review that identifies scientific, clinical, regulatory, or operational gaps before investor engagement.

Yes, we provide analytical and clinical development forecasting with scenario-based budget planning.

Investor Readiness Consulting

Talk to hVIVO

Enquire now